Effects of lipid-lowering drugs on high-density lipoprotein subclasses in healthy men - A randomized trial

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Berthold, Heiner K ^a   Rizzo, Manfredi ^b,c   Spenrath, Nadine ^d   Montalto, Giuseppe ^b   Krone, Wilhelm ^d   Gouni Berthold, Ioanna ^d  

^a EVANGELISCHES KRANKENHAUS   (Germany)

^b UNIVERSITY OF PALERMO   (Italy)

^c Euro Mediterranean Institute of Science and Technology   (Italy)

^d UNIVERSITY OF COLOGNE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EZETIMIBE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; SIMVASTATIN; TRIACYLGLYCEROL; ADIPOCYTOKINE; ANTILIPEMIC AGENT; AZETIDINE DERIVATIVE; BIOLOGICAL MARKER; GLUCOSE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DRUG EFFECT; EVENING DOSAGE; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; DRUG COMBINATION; METABOLISM; NORMAL HUMAN;

ADIPOKINES; ADULT; AZETIDINES; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; GLUCOSE; HEALTHY VOLUNTEERS; HUMANS; HYPERCHOLESTEROLEMIA; HYPOLIPIDEMIC AGENTS; LIPOPROTEINS, HDL; MALE; SIMVASTATIN;

EID: 84899708882     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0091565     Document Type: Article

References (49)

1. Vergeer M, Holleboom AG, Kastelein JJ, Kuivenhoven JA (2010) The HDL hypothesis: does high-density lipoprotein protect from atherosclerosis? J Lipid Res 51: 2058-2073.
2. deGoma EM, deGoma RL, Rader DJ (2008) Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 51: 2199-2211. (Pubitemid 351754991)
3. Frikke-Schmidt R (2010) Genetic variation in the ABCA1 gene, HDL cholesterol, and risk of ischemic heart disease in the general population. Atherosclerosis 208: 305-316.
4. Johannsen TH, Kamstrup PR, Andersen RV, Jensen GB, Sillesen H, et al. (2009) Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease. J Clin Endocrinol Metab 94: 1264-1273.
5. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, et al. (2012) Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 380: 572-580.
6. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, et al. (2007) Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 357: 2109-2122. (Pubitemid 350146106)
7. Ginsberg HN, Elam MB, Lovato LC, Crouse JR III, Leiter LA, et al. (2010) Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362: 1563-1574.
8. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, et al. (2007) Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 356: 1304-1316. (Pubitemid 46513296)
9. Rosenson RS, Brewer HB Jr, Chapman MJ, Fazio S, Hussain MM, et al. (2011) HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 57: 392-410.
10. Angeloni E, Paneni F, Landmesser U, Benedetto U, Melina G, et al. (2013) Lack of protective role of HDL-C in patients with coronary artery disease undergoing elective coronary artery bypass grafting. Eur Heart J 34: 3557-3562.
11. Vickers KC, Remaley AT (2014) HDL and cholesterol: life after the divorce. J Lipid Res 55: 4-12.
12. Mackey RH, Greenland P, Goff DC Jr, Lloyd-Jones D, Sibley CT, et al. (2012) High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis). J Am Coll Cardiol 60: 508-516.
13. Mora S, Glynn RJ, Ridker PM (2013) High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation 128: 1189-1197.
14. Berneis K, Rizzo M, Berthold HK, Spinas GA, Krone W, et al. (2010) Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. Eur Heart J 31: 1633-1639.
15. Rizzo M, Berneis K (2006) The clinical relevance of low-density- lipoproteins size modulation by statins. Cardiovasc Drugs Ther 20: 205-217. (Pubitemid 44121036)
16. Harangi M, Seres I, Harangi J, Paragh G (2009) Benefits and difficulties in measuring HDL subfractions and human paraoxonase-1 activity during statin treatment. Cardiovasc Drugs Ther 23: 501-510.
17. Mikhailidis DP, Wierzbicki AS, Daskalopoulou SS, Al-Saady N, Griffiths H, et al. (2005) The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel. Curr Med Res Opin 21: 959-969. (Pubitemid 40896244)
18. Toth PP, Davidson MH (2005) Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin Pharmacother 6: 131-139.
19. Oravec S, Dostal E, Dukat A, Gavornik P, Kucera M, et al. (2011) HDL subfractions analysis: a new laboratory diagnostic assay for patients with cardiovascular diseases and dyslipoproteinemia. Neuro Endocrinol Lett 32: 502-509.
20. Rye KA, Barter PJ (2014) Cardioprotective functions of HDL. J Lipid Res 55: 168-179.
21. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, et al. (2004) High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 24: 2181-2187. (Pubitemid 39482449)
22. Otvos JD, Collins D, Freedman DS, Shalaurova I, Schaefer EJ, et al. (2006) Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 113: 1556-1563. (Pubitemid 43739414)
23. Blackburn P, Lemieux I, Lamarche B, Bergeron J, Perron P, et al. (2012) Angiographically-assessed coronary artery disease associates with HDL particle size in women. Atherosclerosis 223: 359-364.
24. El Harchaoui K, Arsenault BJ, Franssen R, Despres JP, Hovingh GK, et al. (2009) High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med 150: 84-93.
25. Goliasch G, Oravec S, Blessberger H, Dostal E, Hoke M, et al. (2012) Relative importance of different lipid risk factors for the development of myocardial infarction at a very young age (
26. Mora S, Buring JE, Ridker PM, Cui Y (2011) Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels: a cohort study. Ann Intern Med 155: 742-750.
27. Tomassini JE, Mazzone T, Goldberg RB, Guyton JR, Weinstock RS, et al. (2009) Effect of ezetimibe/simvastatin compared with atorvastatin on lipoprotein subclasses in patients with type 2 diabetes and hypercholesterolaemia. Diabetes Obes Metab 11: 855-864.
28. Gouni-Berthold I, Berthold HK, Gylling H, Hallikainen M, Giannakidou E, et al. (2008) Effects of ezetimibe and/or simvastatin on LDL receptor protein expression and on LDL receptor and HMG-CoA reductase gene expression: a randomized trial in healthy men. Atherosclerosis 198: 198-207. (Pubitemid 351406373)
29. Berthold HK, Naini A, Di Mauro S, Hallikainen M, Gylling H, et al. (2006) Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial. Drug Saf 29: 703-712. (Pubitemid 44175041)
30. Kalogirou M, Tsimihodimos V, Gazi I, Filippatos T, Saougos V, et al. (2007) Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr Med Res Opin 23: 1169-1176. (Pubitemid 46799601)
31. Mikhailidis DP, Elisaf M, Rizzo M, Berneis K, Griffin B, et al. (2011) "European panel on low density lipoprotein (LDL) subclasses": a statement on the pathophysiology, atherogenicity and clinical significance of LDL subclasses: executive summary. Curr Vasc Pharmacol 9: 531-532.
32. Dormans TP, Swinkels DW, de Graaf J, Hendriks JC, Stalenhoef AF, et al. (1991) Single-spin density-gradient ultracentrifugation vs gradient gel electrophoresis: two methods for detecting low-density-lipoprotein heterogeneity compared. Clin Chem 37: 853-858. (Pubitemid 21925928)
33. Gouni-Berthold I, Berthold HK, Chamberland JP, Krone W, Mantzoros CS (2008) Short-term treatment with ezetimibe, simvastatin or their combination does not alter circulating adiponectin, resistin or leptin levels in healthy men. Clin Endocrinol (Oxf) 68: 536-541. (Pubitemid 351388705)
34. Kwiterovich PO Jr (2000) The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review. Am J Cardiol 86: 5L-10L.
35. Cheung MC, Austin MA, Moulin P, Wolf AC, Cryer D, et al. (1993) Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia. Atherosclerosis 102: 107-119. (Pubitemid 23269736)
36. Neuman MP, Neuman HR, Neuman J (1991) Significant increase of high-density lipoprotein2-cholesterol under prolonged simvastatin treatment. Atherosclerosis 91 Suppl: S11-S19.
37. Harangi M, Mirdamadi HZ, Seres I, Sztanek F, Molnar M, et al. (2009) Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity. Transl Res 153: 190-198.
38. McKenney JM, McCormick LS, Schaefer EJ, Black DM, Watkins ML (2001) Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. Am J Cardiol 88: 270-274. (Pubitemid 32721954)
39. Kostapanos MS, Milionis HJ, Filippatos TD, Christogiannis LG, Bairaktari ET, et al. (2009) Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia. J Cardiovasc Pharmacol Ther 14: 5-13.
40. Soedamah-Muthu SS, Colhoun HM, Thomason MJ, Betteridge DJ, Durrington PN, et al. (2003) The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis 167: 243-255. (Pubitemid 36773524)
41. Farnier M, Perevozskaya I, Taggart WV, Kush D, Mitchel YB (2008) VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate. J Lipid Res 49: 2641-2647.
42. Nakou ES, Filippatos TD, Georgoula M, Kiortsis DN, Tselepis AD, et al. (2008) The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Curr Med Res Opin 24: 1919-1929.
43. Knapp HH, Schrott H, Ma P, Knopp R, Chin B, et al. (2001) Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 110: 352-360. (Pubitemid 32248724)
44. Bays HE, Moore PB, Drehobl MA, Rosenblatt S, Toth PD, et al. (2001) Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 23: 1209-1230. (Pubitemid 32804115)
45. Movva R, Rader DJ (2008) Laboratory assessment of HDL heterogeneity and function. Clin Chem 54: 788-800. (Pubitemid 351671595)
46. Gentile M, Panico S, Jossa F, Mattiello A, Ubaldi S, et al. (2008) Small dense LDL particles and metabolic syndrome in a sample of middle-aged women. Findings from Progetto Atena. Clin Chim Acta 388: 179-183. (Pubitemid 350266592)
47. Oravec S, Krivosikova Z, Krivosik M, Gruber K, Gruber M, et al. (2011) Lipoprotein profile in patients who survive a stroke. Neuro Endocrinol Lett 32: 496-501.
48. Varady KA, Bhutani S, Klempel MC, Kroeger CM (2011) Comparison of effects of diet versus exercise weight loss regimens on LDL and HDL particle size in obese adults. Lipids Health Dis 10: 119.
49. van de Woestijne AP, van der Graaf Y, Liem AH, Cramer MJ, Westerink J, et al. (2013) Low HDL-cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication. J Am Coll Cardiol 62: 1834-1841.